Double-blind placebo controlled randomized withdrawal trial assessing the efficacy and tolerability of 'on demand' maintenance therapy with 10mg o.d. rabeprazole for 6 months in non-erosive reflux disease patients with complete symptom relief after 4 week open acute phase
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2007
At a glance
- Drugs Rabeprazole (Primary)
- Indications Gastro-oesophageal reflux; Heartburn
- Focus Therapeutic Use
- 20 Nov 2005 New trial record.